MSH2 and colorectal carcinoma: In addition, due to the lack of IHC and clinical information (e.g., KRAS, BRAF mutations, and Lynch syndrome status) in the validation datasets, the characteristics of samples with incorrectly predicted MSI status (e.g., MSH2/MSH6-negative CRC) could not be thoroughly assessed.